High Level of Circulating Vitamin D During Neoadjuvant Therapy May Lower Risk of Metastatic Progression in High-Risk Rectal Cancer

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5724-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Systemic Immune Response Induced by Oxaliplatin-Based Neoadjuvant Therapy Favours Survival Without Metastatic Progression in High-Risk Rectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer With High Risk Factors in Slovenia

Radiology and Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Monthly High-Dose Vitamin D Supplementation and Cancer Risk

JAMA Oncology
Cancer ResearchOncology
2018English

Neoadjuvant and Adjuvant Chemohormonal Therapy in Patients With High-Risk and Very High-Risk Prostate Cancer: Our Experience

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2018English

Oncological Results of Neoadjuvant Chemohormonal Therapy in Patients With High and Very High-Risk Prostate Cancer

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2020English

Vitamin D Is Associated With a Lower Risk of Cancer

BMJ
2006English

High Cholesterol May Increase Risk of Testicular Cancer

BMJ
2005English

Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men With Clinically High-Risk Prostate Cancer Treated With Radical Prostatectomy

European Urology
Urology
2008English

Possible Risk Factors Associated With Relapse in Patients Treated With Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer

The Open Prostate Cancer Journal
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy